XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Cash Flows From Operating Activities:        
Net loss $ (7,726,000) $ (3,303,000) $ (21,206,000) $ (12,864,000)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation     509,000 407,000
Income tax benefit   (527,000)   (1,216,000)
In-process research and development impairment 1,325,000   1,325,000  
Goodwill impairment 1,526,000   5,594,000  
Change in fair value of contingent consideration     514,000 (999,000)
Non-cash lease expense     335,000 283,000
Depreciation     110,000 96,000
Deferred research and development tax credit (221,000)   (669,000)  
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets     1,124,000 1,524,000
Deposits and other assets     1,000 (54,000)
Accounts payable     (21,000) (74,000)
Accrued expenses     724,000 883,000
Accrued employee benefits     (229,000) (129,000)
Operating lease liability     (357,000) (312,000)
Net Cash Used In Operating Activities     (12,246,000) (12,455,000)
Cash Flows from Investing Activities        
Purchase of property and equipment     (1,000) (146,000)
Net Cash Used in Investing Activities     (1,000) (146,000)
Cash Flows from Financing Activities        
Payment of loans payable     (67,000) (75,000)
Proceeds from issuance Common Stock and Warrants offering, net of issuance costs     1,953,000  
Proceeds from issuance ATM offering, net of issuance costs     3,603,000 2,157,000
Net Cash provided by Financing Activities     5,489,000 2,082,000
Effects of exchange rate changes on cash and cash equivalents     (9,000) (109,000)
Net decrease in cash and cash equivalents and restricted cash     (6,767,000) (10,628,000)
Cash and cash equivalents and restricted at the beginning of this period     23,279,000 41,885,000
Cash and cash equivalents and restricted cash at the end of this period 16,512,000 31,257,000 16,512,000 31,257,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet        
Cash and cash equivalents 16,409,000 31,160,000 16,409,000 31,160,000
Restricted cash included in other long-term assets 103,000 97,000 103,000 97,000
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows 16,512,000 $ 31,257,000 16,512,000 31,257,000
Supplemental non-cash investing and financing activities:        
Right of use assets obtained in exchange for lease liabilities     937,000 $ 937,000
Series C Preferred Stock        
Supplemental non-cash investing and financing activities:        
Conversion of Preferred Stock to Common Shares 1,000,000.0   2,005,000  
Series D Preferred Stock        
Supplemental non-cash investing and financing activities:        
Conversion of Preferred Stock to Common Shares $ 728,000   $ 728,000